Sai Life Sciences Limited

Sai Life Sciences Limited announced the allotment of 14,600 shares under the Employees Stock Option Plan 2008 and 66,000 shares under the Management Employee Stock Option Plan 2018, increasing the company’s issued, subscribed, and paid-up equity share capital from Rs 21,23,13,617 to Rs 21,23,94,216. The exercise price was Rs 188.90 per share for the ESOP 2008 allotment and Rs 23.30 per share for the MESOP 2018 allotment, with a premium of Rs 187.90 and Rs 22.30 respectively.

Sai Life Sciences Ltd rose for a third straight session today. The stock is quoting at Rs 1467.4, up 1.59% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.77% on the day, quoting at 24283.3. The Sensex is at 77581.77, down 0.73%. Sai Life Sciences Ltd has added around 15.35% in last one month. Meanwhile, Nifty Pharma index of which Sai Life Sciences Ltd is a constituent, has added around 3.88% in last one month and is currently quoting at 26750.45, down 0.42% on the day. The volume in the stock stood at 2.73 lakh shares today, compared to the daily average of 5.5 lakh shares in last one month.The PE of the stock is 85.03 based on TTM earnings ending June 26.

Sai Life Sciences Ltd gained for a third straight session today. The stock is quoting at Rs 1383, up 1.21% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.37% on the day, quoting at 24523.85. The Sensex is at 78409.43, down 0.02%. Sai Life Sciences Ltd has risen around 12.2% in last one month. Meanwhile, Nifty Pharma index of which Sai Life Sciences Ltd is a constituent, has risen around 2.37% in last one month and is currently quoting at 26597.5, down 0.44% on the day. The volume in the stock stood at 1.7 lakh shares today, compared to the daily average of 3.72 lakh shares in last one month.The PE of the stock is 83.34 based on TTM earnings ending March 26.

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 6 August 2026.

Sai Life Sciences has allotted 92,000 equity shares under ESOP on 14 May 2026. With this allotment, the paid up equity share capital has increased to 21,21,15,515 equity shares of Re 1 each.

Net profit of Sai Life Sciences rose 18.09% to Rs 104.24 crore in the quarter ended March 2026 as against Rs 88.27 crore during the previous quarter ended March 2025. Sales rose 3.91% to Rs 602.14 crore in the quarter ended March 2026 as against Rs 579.51 crore during the previous quarter ended March 2025. For the full year,net profit rose 105.08% to Rs 348.91 crore in the year ended March 2026 as against Rs 170.13 crore during the previous year ended March 2025. Sales rose 29.38% to Rs 2192.49 crore in the year ended March 2026 as against Rs 1694.57 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales602.14579.51 4 2192.491694.57 29 OPM %29.3227.19 -28.7923.94 - PBDT184.25156.29 18 641.05366.28 75 PBT138.94118.80 17 474.19227.70 108 NP104.2488.27 18 348.91170.13 105 Powered by Capital Market - Live

Sai Life Sciences will hold a meeting of the Board of Directors of the Company on 14 May 2026.

Sai Life Sciences has allotted 11,100 equity shares under ESOP on 24 March 2026. With this allotment, the paid up equity share capital has increased to 21,17,79,234 equity shares of Re 1 each. Powered by Capital Market - Live

Sai Life Sciences has allotted 129,007 equity shares under ESOP on 22 February 2026. With this allotment, the paid up equity share capital has increased to 21,17,58,134 equity shares of Re 1 each. Powered by Capital Market - Live

On a consolidated basis, the company reported revenue from operations of Rs 556 crore in Q3 FY26, up 27% YoY from Rs 440 crore in Q3 FY25. The company said revenue growth during the quarter was driven by strong momentum in both contract research organisation and contract development and manufacturing organisation segments. Profit after tax stood at Rs 100 crore in Q3 FY26, compared with Rs 54 crore a year ago, translating into an 86% YoY increase. PAT margin improved to 18% from 12% in the corresponding quarter last year. Profit before tax surged 87% YoY to Rs 134 crore in Q3 FY26 from Rs 72 crore in the year-ago quarter. EBITDA increased 54% YoY to Rs 191 crore from Rs 124 crore in Q3 FY25, while EBITDA margin expanded to 34% from 28%. The growth was supported by improved capacity utilization, operational efficiencies, and ongoing cost optimization initiatives. Sai Life Sciences said it has invested Rs 405 crore in capital expenditure so far, against a planned capex outlay of Rs 700 crore for FY26, in line with its long-term strategy to strengthen capabilities and expand capacity. During the quarter, it successfully completed eight customer audits across its manufacturing and R&D units, with zero data integrity deviations and no critical observations reported. Krishna Kanumuri, managing director and CEO, Sai Life Sciences, said: Q3 FY26 marked continued progress in building Sai Life Sciences into a science-led, globally relevant CRDMO. Looking ahead, we remain confident in sustaining our growth momentum in the coming year. With disciplined execution and a clear strategic direction, Sai Life Sciences is well positioned to support the next phase of innovation while creating long-term value for all stakeholders. Hyderabad-based Sai Life Sciences is one of India's fastest growing Contract Research, Development, and Manufacturing Organizations (CRDMO) that partners with innovator pharmaceutical and biotech companies to accelerate the discovery, development, and commercialization of new medicines. Powered by Capital Market - Live